217 related articles for article (PubMed ID: 32184261)
1. EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.
O'Regan L; Barone G; Adib R; Woo CG; Jeong HJ; Richardson EL; Richards MW; Muller PAJ; Collis SJ; Fennell DA; Choi J; Bayliss R; Fry AM
J Cell Sci; 2020 May; 133(9):. PubMed ID: 32184261
[TBL] [Abstract][Full Text] [Related]
2. The mesenchymal morphology of cells expressing the EML4-ALK V3 oncogene is dependent on phosphorylation of Eg5 by NEK7.
Pashley SL; Papageorgiou S; O'Regan L; Barone G; Robinson SW; Lucken K; Straatman KR; Roig J; Fry AM
J Biol Chem; 2024 May; 300(5):107144. PubMed ID: 38458397
[TBL] [Abstract][Full Text] [Related]
3. EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity.
Lucken K; O'Regan L; Choi J; Sampson J; Pashley SL; Bayliss R; Khan S; Fry AM
Mol Cancer Res; 2022 Jun; 20(6):854-866. PubMed ID: 35656694
[TBL] [Abstract][Full Text] [Related]
4. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
Zhang SS; Nagasaka M; Zhu VW; Ou SI
Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
[TBL] [Abstract][Full Text] [Related]
5. EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK
Christopoulos P; Endris V; Bozorgmehr F; Elsayed M; Kirchner M; Ristau J; Buchhalter I; Penzel R; Herth FJ; Heussel CP; Eichhorn M; Muley T; Meister M; Fischer JR; Rieken S; Warth A; Bischoff H; Schirmacher P; Stenzinger A; Thomas M
Int J Cancer; 2018 Jun; 142(12):2589-2598. PubMed ID: 29363116
[TBL] [Abstract][Full Text] [Related]
6. Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain.
Richards MW; O'Regan L; Roth D; Montgomery JM; Straube A; Fry AM; Bayliss R
Biochem J; 2015 May; 467(3):529-36. PubMed ID: 25740311
[TBL] [Abstract][Full Text] [Related]
7. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.
Li T; Maus MK; Desai SJ; Beckett LA; Stephens C; Huang E; Hsiang J; Zeger G; Danenberg KD; Astrow SH; Gandara DR
J Thorac Oncol; 2014 Jan; 9(1):18-25. PubMed ID: 24346090
[TBL] [Abstract][Full Text] [Related]
8. Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer.
Tan S; Sun D; Pu W; Gou Q; Guo C; Gong Y; Li J; Wei YQ; Liu L; Zhao Y; Peng Y
Mol Cancer; 2018 Sep; 17(1):138. PubMed ID: 30236141
[TBL] [Abstract][Full Text] [Related]
9. Correlation of anaplastic lymphoma kinase overexpression and the EML4-ALK fusion gene in non-small cell lung cancer by immunohistochemical study.
Chen TD; Chang IC; Liu HP; Wu YC; Wang CL; Chen YT; Chen YR; Huang SF
Chang Gung Med J; 2012; 35(4):309-17. PubMed ID: 22913857
[TBL] [Abstract][Full Text] [Related]
10. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
[TBL] [Abstract][Full Text] [Related]
11. Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.
Guo Y; Ma J; Lyu X; Liu H; Wei B; Zhao J; Fu S; Ding L; Zhang J
BMC Cancer; 2014 Nov; 14():834. PubMed ID: 25407901
[TBL] [Abstract][Full Text] [Related]
12. Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.
Sampson J; Richards MW; Choi J; Fry AM; Bayliss R
EMBO Rep; 2021 Dec; 22(12):e53693. PubMed ID: 34661367
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
Choi YL; Takeuchi K; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Hamada T; Haruta H; Watanabe H; Kurashina K; Hatanaka H; Ueno T; Takada S; Yamashita Y; Sugiyama Y; Ishikawa Y; Mano H
Cancer Res; 2008 Jul; 68(13):4971-6. PubMed ID: 18593892
[TBL] [Abstract][Full Text] [Related]
14. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
Lin E; Li L; Guan Y; Soriano R; Rivers CS; Mohan S; Pandita A; Tang J; Modrusan Z
Mol Cancer Res; 2009 Sep; 7(9):1466-76. PubMed ID: 19737969
[TBL] [Abstract][Full Text] [Related]
15. The biology and treatment of EML4-ALK non-small cell lung cancer.
Sasaki T; Rodig SJ; Chirieac LR; Jänne PA
Eur J Cancer; 2010 Jul; 46(10):1773-80. PubMed ID: 20418096
[TBL] [Abstract][Full Text] [Related]
16. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
Wong DW; Leung EL; So KK; Tam IY; Sihoe AD; Cheng LC; Ho KK; Au JS; Chung LP; Pik Wong M;
Cancer; 2009 Apr; 115(8):1723-33. PubMed ID: 19170230
[TBL] [Abstract][Full Text] [Related]
17. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
[TBL] [Abstract][Full Text] [Related]
18. Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.
Cheon SY; Kwon S
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982897
[TBL] [Abstract][Full Text] [Related]
19. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
20. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
